Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Arrowhead PharmaceuticalsUnited TherapeuticsIonis PharmaceuticalsSarepta TherapeuticsGW Pharmaceuticals
SymbolNASDAQ:ARWRNASDAQ:UTHRNASDAQ:IONSNASDAQ:SRPTNASDAQ:GWPH
Price Information
Current Price$66.75$202.52$41.27$72.83$218.70
52 Week RangeBuyBuyHoldBuyHold
MarketRank™
Overall Score1.51.51.61.91.5
Analysis Score3.42.54.14.32.1
Community Score2.52.22.33.13.0
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.71.71.7
Earnings & Valuation Score0.01.30.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyHold
Consensus Price Target$85.31$219.57$57.91$150.48$204.09
% Upside from Price Target27.80% upside8.42% upside40.32% upside106.61% upside-6.68% downside
Trade Information
Market Cap$6.97 billion$9.03 billion$5.89 billion$5.83 billion$6.85 billion
Beta1.620.521.422.012.15
Average Volume812,000391,1991,213,6872,017,178975,515
Sales & Book Value
Annual Revenue$87.99 million$1.45 billion$1.12 billion$380.83 million$311.33 million
Price / Sales78.746.235.1815.1922.02
CashflowN/AN/A$1.68 per shareN/A$0.01 per share
Price / CashN/AN/A24.55N/A18,588.22
Book Value$4.51 per share$63.36 per share$11.98 per share$10.98 per share$23.48 per share
Price / Book14.803.203.446.639.31
Profitability
Net Income$-84,550,000.00$-104,500,000.00$303.26 million$-715,080,000.00$-9,020,000.00
EPS($0.84)($2.39)$2.08($9.71)($0.24)
Trailing P/E RatioN/A19.1685.98N/AN/A
Forward P/E RatioN/A17.47N/AN/A607.50
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-96.09%33.25%7.82%-121.30%-11.05%
Return on Equity (ROE)-17.37%15.48%6.57%-61.62%-7.46%
Return on Assets (ROA)-15.19%11.31%3.39%-23.02%-6.13%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.24%0.51%0.79%0.01%
Current Ratio7.92%7.22%10.37%6.14%5.13%
Quick Ratio7.92%6.88%10.28%5.56%4.31%
Ownership Information
Institutional Ownership Percentage65.52%90.09%84.14%89.69%81.00%
Insider Ownership Percentage4.00%10.90%2.40%5.90%3.10%
Miscellaneous
Employees2329507577431,161
Shares Outstanding103.79 million44.54 million140.86 million79.42 million31.35 million
Next Earnings Date5/6/2021 (Estimated)5/5/2021 (Estimated)5/5/2021 (Estimated)5/5/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
GW Pharmaceuticals (NASDAQ:GWPH) Hits New 52-Week High at $219.00GW Pharmaceuticals (NASDAQ:GWPH) Hits New 52-Week High at $219.00
americanbankingnews.com - April 15 at 10:52 AM
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 ...GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 ...
apnews.com - April 13 at 11:35 AM
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual MeetingGW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting
finance.yahoo.com - April 13 at 11:35 AM
JAZZs Xywav sNDA for Hypersomnia Gets FDA Priority ReviewJAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review
finance.yahoo.com - April 13 at 11:35 AM
Healthcare Investors: Heres What You Need to Know About Medical MarijuanaHealthcare Investors: Here's What You Need to Know About Medical Marijuana
finance.yahoo.com - April 11 at 9:31 AM
Jazz Securities Designated Activity Company -- Moodys assigns Ba2 to Jazz Pharmas new secured credit facilities; negative outlookJazz Securities Designated Activity Company -- Moody's assigns Ba2 to Jazz Pharma's new secured credit facilities; negative outlook
finance.yahoo.com - April 9 at 7:38 PM
Douglas B. Snyder Sells 8,400 Shares of GW Pharmaceuticals plc (NASDAQ:GWPH) StockDouglas B. Snyder Sells 8,400 Shares of GW Pharmaceuticals plc (NASDAQ:GWPH) Stock
americanbankingnews.com - April 8 at 10:46 PM
The Benefits of Medical Marijuana, for Patients and Your PortfolioThe Benefits of Medical Marijuana, for Patients and Your Portfolio
finance.yahoo.com - April 5 at 9:41 AM
GW Pharmaceuticals (NASDAQ:GWPH) Reaches New 1-Year High at $218.52GW Pharmaceuticals (NASDAQ:GWPH) Reaches New 1-Year High at $218.52
americanbankingnews.com - April 1 at 10:34 AM
Halper Sadeh LLP Investigates the Following Mergers - COHR, PRSP, HWCC, GWPH; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP Investigates the Following Mergers - COHR, PRSP, HWCC, GWPH; Shareholders are Encouraged to Contact the Firm
marketwatch.com - March 31 at 4:21 AM
Volker Knappertz Sells 3,060 Shares of GW Pharmaceuticals plc (NASDAQ:GWPH) StockVolker Knappertz Sells 3,060 Shares of GW Pharmaceuticals plc (NASDAQ:GWPH) Stock
americanbankingnews.com - March 30 at 10:56 PM
Halper Sadeh LLP Investigates the Following Mergers – COHR, PRSP, HWCC, GWPH; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP Investigates the Following Mergers – COHR, PRSP, HWCC, GWPH; Shareholders are Encouraged to Contact the Firm
finance.yahoo.com - March 30 at 8:14 AM
GW Pharmaceuticals (NASDAQ:GWPH) Hits New 52-Week High at $217.82GW Pharmaceuticals (NASDAQ:GWPH) Hits New 52-Week High at $217.82
americanbankingnews.com - March 26 at 5:46 PM
Head to Head Contrast: GW Pharmaceuticals (NASDAQ:GWPH) versus Atossa Therapeutics (NASDAQ:ATOS)Head to Head Contrast: GW Pharmaceuticals (NASDAQ:GWPH) versus Atossa Therapeutics (NASDAQ:ATOS)
americanbankingnews.com - March 25 at 4:56 PM
GW Pharmaceuticals (NASDAQ:GWPH) and Atossa Therapeutics (NASDAQ:ATOS) Critical AnalysisGW Pharmaceuticals (NASDAQ:GWPH) and Atossa Therapeutics (NASDAQ:ATOS) Critical Analysis
americanbankingnews.com - March 25 at 4:56 PM
INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRAH, JCS, GWPH, CRHM, EGOV; Shareholders are Encouraged to Contact the FirmINVESTIGATION ALERT: Halper Sadeh LLP Investigates PRAH, JCS, GWPH, CRHM, EGOV; Shareholders are Encouraged to Contact the Firm
finance.yahoo.com - March 25 at 8:14 AM
The Medical Marijuana Stock to Buy Before the Schedule I ChangeThe Medical Marijuana Stock to Buy Before the Schedule I Change
moneymorning.com - March 24 at 3:21 PM
GW Pharmaceuticals (NASDAQ:GWPH) Sees Large Volume IncreaseGW Pharmaceuticals (NASDAQ:GWPH) Sees Large Volume Increase
americanbankingnews.com - March 24 at 11:54 AM
GW Pharmaceuticals PLC Stock Is Estimated To Be Possible Value TrapGW Pharmaceuticals PLC Stock Is Estimated To Be Possible Value Trap
finance.yahoo.com - March 23 at 7:06 PM
Cabot Brown Sells 4,020 Shares of GW Pharmaceuticals plc (NASDAQ:GWPH) StockCabot Brown Sells 4,020 Shares of GW Pharmaceuticals plc (NASDAQ:GWPH) Stock
americanbankingnews.com - March 22 at 10:26 PM
GWPH Jan 2022 50.000 putGWPH Jan 2022 50.000 put
sg.finance.yahoo.com - March 21 at 7:29 PM
GWPH Jan 2022 300.000 callGWPH Jan 2022 300.000 call
sg.finance.yahoo.com - March 21 at 2:29 PM
Is There An Opportunity With GW Pharmaceuticals plcs (NASDAQ:GWPH) 46% Undervaluation?Is There An Opportunity With GW Pharmaceuticals plc's (NASDAQ:GWPH) 46% Undervaluation?
finance.yahoo.com - March 10 at 7:05 PM
New Approaches to Mental Health are Changing the Healthcare SpaceNew Approaches to Mental Health are Changing the Healthcare Space
prnewswire.com - March 9 at 9:28 AM
GW Pharma Wants Out Of Canopys CBD Patent DisputeGW Pharma Wants Out Of Canopy's CBD Patent Dispute
law360.com - March 8 at 6:37 PM
DateCompanyBrokerageAction
2/8/2021Arrowhead PharmaceuticalsCitigroupBoost Price Target
2/8/2021Arrowhead PharmaceuticalsB. RileyBoost Price Target
2/5/2021Arrowhead PharmaceuticalsPiper SandlerBoost Price Target
2/5/2021Arrowhead PharmaceuticalsChardan CapitalBoost Price Target
2/5/2021Arrowhead PharmaceuticalsHC WainwrightBoost Price Target
12/21/2020Arrowhead PharmaceuticalsRobert W. BairdDowngrade
12/15/2020Arrowhead PharmaceuticalsUBS GroupInitiated Coverage
11/24/2020Arrowhead PharmaceuticalsRoyal Bank of CanadaBoost Price Target
11/24/2020Arrowhead PharmaceuticalsCantor FitzgeraldBoost Price Target
11/24/2020Arrowhead PharmaceuticalsSVB LeerinkLower Price Target
11/19/2020Arrowhead PharmaceuticalsSmith Barney CitigroupInitiated Coverage
11/19/2020Arrowhead PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
5/8/2020Arrowhead PharmaceuticalsOppenheimerUpgrade
4/14/2021United TherapeuticsJPMorgan Chase & Co.Boost Price Target
3/1/2021United TherapeuticsCredit Suisse GroupBoost Price Target
2/25/2021United TherapeuticsWedbushBoost Price Target
1/20/2021United TherapeuticsCowenBoost Price Target
1/20/2021United TherapeuticsLADENBURG THALM/SH SHBoost Price Target
3/10/2020United TherapeuticsJefferies Financial GroupUpgrade
3/29/2021Ionis PharmaceuticalsMorgan StanleyLower Price Target
3/29/2021Ionis PharmaceuticalsNeedham & Company LLCLower Price Target
3/29/2021Ionis PharmaceuticalsBMO Capital MarketsLower Price Target
3/23/2021Ionis PharmaceuticalsBarclaysLower Price Target
3/4/2021Sarepta TherapeuticsMizuhoBoost Price Target
1/8/2021Sarepta TherapeuticsRaymond JamesDowngrade
2/3/2021GW PharmaceuticalsNorthland SecuritiesDowngrade
8/10/2020GW PharmaceuticalsGuggenheimLower Price Target
8/7/2020GW PharmaceuticalsThe Goldman Sachs GroupSet Price Target
8/7/2020GW PharmaceuticalsBank of AmericaReiterated Rating
7/14/2020GW PharmaceuticalsStifel NicolausDowngrade
6/30/2020GW PharmaceuticalsEvercore ISIBoost Price Target
(Data available from 4/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.